Full Fed. Circ. To Review On-Sale Bar In Angiomax Patent Suit

The full Federal Circuit on Friday agreed to review a panel decision overruling a trial judge and invalidating two of The Medicines Co.'s patents for the blood-thinning drug Angiomax, positioning the...

Already a subscriber? Click here to view full article